StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)

Close on Nov 17, 2026Market cap $73.93MP/E –Yield –

Coherus Oncology price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Coherus Oncology's price to book ratio was 1.5× on Nov 11, 2026, against 1.8× a year earlier. Over the last 5 years it ranged from 1.1× to 68.0×, with a median of 7.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.5×−0.4
2025Dec 31, 20251.9×−50.3
2022Jul 29, 202252.1×+42.8
2021Dec 31, 20219.3×+3.8
2020Dec 31, 20205.5×−62.4
2019Jan 31, 201968.0×+22.3
2018Dec 31, 201845.7×+37.9
2017Dec 29, 20177.8×−28.7
2016Dec 30, 201636.5×+17.6
2015Dec 31, 201518.8×–

More Coherus Oncology figures

See a number that looks wrong?